Abstract: A pharmaceutical composition, especially a pharmaceutical composition for the alleviation or treatment of symptoms due to ischemic diseases and symptoms derived from seizures, epilepsy, and migraine, and a Ca2+ overload suppressant, containing an arylpiperidinol or arylpiperidine derivative having the formula (I): 1

Abstract: Sustained release formulation containing tacrolimus or its hydrate is provided. The time (T63.2%) required for 63.2% of the maximum amount of tacrolimus or its hydrate to be dissolved is 0.7 to 15 hours. The time is measured in accordance to the Japanese Pharmacopoeia, the 13-th edition, Dissolution Test, No. 2 (Puddle method, 50 rpm) using an aqueous 0.005% hydroxypropyl cellulose solution. This aqueous test solution is adjusted to pH 4.5, accordingly. The formulation further comprise a solid base which is a water-soluble polymer and/or wax. The formulation is in the form of a powder, fine powder, granule, tablet or capsule. Furthermore, the formulation is administered to a patient once a day for preventing organ or tissue rejection by transplantation or autoimmune diseases.

Abstract: A compound having the formula (I) or its salt, hydrate, hydrate salt or solvate: wherein R1 to R4 independently represent H, halogen, OH, alkoxy, optionally substituted alkyl, aryl, or aralkyl group, R5 represents H, optionally substituted alkyl, aryl, or aralkyl group, E1 represents O, S, or —NR6, where R6 represents H, an optionally substituted alkyl, aryl, or aralkyl group, E2 represents O, S, or —NR7, where R7 represents H, an optionally substituted alkyl, aryl, or aralkyl group, A represents CH, C(OH), or N, X represents H, halogen, alkoxy, or an optionally substituted alkyl group, and Q represents an optionally substituted phenyl group, phenoxy, phenylmethyl, or cycloalkyloxy group, where when E1 represents O or S, E2 does not represent O or S, which has an action of suppressing the cytotoxic Ca2+ overload and lipid peroxidation and effective for pharmaceutical preparation for the alleviation and treatment of symptoms due to ischemic diseases, etc.

Abstract: In an imaging method including the steps of irradiating light from light emitting means (4) to a target object to be imaged (S) such as a cardboard box, including an identifier marking (3) at a second portion (d2) thereof printed on a first portion (d1) constituting an ornamental design (2) printed on a cardboard box side face (1A) and then receiving the reflected light therefrom by light receiving means (5) so as to image the object (S), the first portion (d1) and the second portion (d2) are provided with different reflection factors for the near-infrared range light from each other. The light emitted from the light emitting means (4) includes a near-infrared range light component and the light receiving means (5) receives the near-infrared range light component for the imaging. With these, even when the marking is printed on a background having a dark color, the marking can be detected accurately and reliably as being distinct from the background.

Abstract: The present invention relates to a method and an apparatus for imaging a liquid-filling container in which a light emitting unit (2) is provided for emitting and irradiating light onto the container (B) and a light receiving unit (3) is provided for receiving the light transmitted through the container. The object of the present invention is to provide such a method and an apparatus for imaging a liquid-filling container which method and apparatus assure reliable detection of the surface of liquid filled in a container or of foreign substance mixed in the liquid or present in the container or the container material not only when the container is transparent, but also when the container is a colored container of a dark color such as black, dark green or dark brown or the container has a frosted surface or when the liquid filled in the container has a dark color.

Abstract: A medicine having the following basic structure, for the alleviation or treatment of symptoms derived from ischemic diseases and seizures, epilepsy, and migraine, having a powerful action in suppressing cytotoxic Ca2+ overload and free from side-effects: wherein Z═C, CH, or N, X═O or CH2, E and Y═H, OH, a halogen, alkoxy, alkyl, or a halogen-substituted alkyl.

Abstract: A pharmaceutical composition, especially a pharmaceutical composition for the alleviation or treatment of symptoms due to ischemic diseases and symptoms derived from seizures, epilepsy, and migraine, and a Ca2+ overload suppressant, containing an arylpiperidinol or arylpiperidine derivative having the formula (I): wherein, R is H, an optionally substituted phenyl, an optionally substituted phenoxy, or an optionally substituted benzoyl, A is a connecting bond, a cycloalkylene, or an alkenylene optionally substituted with a lower alkyl, B is an alkylene optionally substituted with OH or an alkoxy or —NHCO(CH2)n— where n is an integer of 1 to 5, E is a connecting bond, O, or a methylene, X is OH or H provided that when E is O or a methylene, X is not H, and Y and Z are independently H, a halogen, an alkoxy, or an alkyl optionally substituted with a halogen.

Abstract: A molding die drive unit capable of both of compressing and expanding (volume enlargement) molten resin in molding die and having thin shape and superior mechanical efficiency, molding unit and molding process are provided. A molding die drive unit 20 for advancing and retracting a movable die 10B relative to a cavity 10C has a large-diameter main cylinder unit 21, and a plurality of small-diameter sub cylinder unit 22 disposed around the main cylinder unit 21. After loading the molten resin, the cylinder units 21 and 22 are driven to advance and retract the movable die 10B to the cavity 10C to compress or expand the molten resin in the cavity to conduct molding process.

Abstract: Providing an oral formulation of a macrolide compound where the dissolution of the macrolide compound is under sustained release; and a sustained-release formulation containing a composition in solid solution, where the macrolide compound is present at an amorphous state in a solid base.

Abstract: A compound having the formula (I) or its salt, hydrate, hydrate salt or solvate: wherein R1 to R4 independently represent H, halogen, OH, alkoxy, optionally substituted alkyl, aryl, or aralkyl group, R5 represents H, optionally substituted alkyl, aryl, or aralkyl group, E1 represents O, S, or —NR6, where R6 represents H, an optionally substituted alkyl, aryl, or aralkyl group, E2 represents O, S, or —NR7, where R7 represents H, an optionally substituted alkyl, aryl, or aralkyl group, A represents CH, C(OH), or N, X represents H, halogen, alkoxy, or an optionally substituted alkyl group, and Q represents an optionally substituted phenyl group, phenoxy, phenylmethyl, or cycloalkyloxy group, where when E1 represents O or S, E2 does not represent O or S, which has an action of suppressing the cytotoxic Ca2+ overload and lipid peroxidation and effective for pharmaceutical preparation for the alleviation and treatment of symptoms due to ischemic diseases, etc.

Abstract: Providing an oral formulation of a macrolide compound where the dissolution of the macrolide compound is under sustained release; and a sustained-release formulation containing a composition in solid solution, where the macrolide compound is present at an amorphous state in a solid base.

Abstract: An apparatus for dispensing drinking water including of a chamber in which a container packed with drinking water is mounted, a conduit connected with the container in the chamber to dispense drinking water through the apparatus, and sterilizer installed adjacent the conduit means to apply sterilization with substantial heat thereto. The sterilizing means may include automatic control system to control automatically sterilizing with heat. The conduit may includes a storage area for storing drinking water within the conduit, and the storage area may includes two tanks for storing drinking water, one is a cold water tank including a refrigeration device to chill the drinking water, and the other is a hot water tank including heating device to heat the drinking water. The sterilization with heat may be done by heating the conduit with heaters installed surrounding thereof, or may be done by circulating hot water which is stored in the hot water tank through the apparatus.

Abstract: A medicine having the following basic structure, for the alleviation or treatment of symptoms derived from ischemic diseases and seizures, epilepsy, and migraine, having a powerful action in suppressing cytotoxic Ca.sup.2+ overload and free from side-effects: ##STR1## wherein Z.dbd.C, CH, or N, X.dbd.O or CH.sub.2, E and Y.dbd.H, OH, a halogen, alkoxy, alkyl, or a halogen-substituted alkyl.

Abstract: In a method of integrally attaching a hollow member to a cast product by casting so that the hollow member communicates with a hollow interior of the cast product, a closure member is fitted into an open end of the hollow member so that the open end of the hollow member is closed by the closure member. The closure member projects from a core for forming the hollow interior of the cast product in a direction different from a direction in which the core is drawn out of the cast product. A molten metal is poured into a casting mold after the casting mold has been clamped. The closure member is moved inside the core after solidification of the molten metal so that the closure member is released from the fitting in the hollow member. The core is drawn out of the solidified metal subsequently to the moving step of the closure member.

Abstract: The compound of the formula (I) or its salt or a medicament containing the same ##STR1## wherein, A and B represent a carbonyl group or sulfonyl group, m and p are different and represent 0 or 1,R.sup.1 and R.sup.2 may be the same or different from each other and represent a hydrogen atom, an unsubstituted or substituted alkyl group, an unsubstituted or substituted aryl group, an unsubstituted or substituted aralkyl group, an unsubstituted or substituted heterocyclic group containing nitrogen or an unsubstituted or substituted heterocyclic group containing oxygen, or R.sup.1 and R.sup.2, taken together with the nitrogen atom to which they are linked, may form an unsubstituted or substituted heterocyclic group, provided that when B is a sulfonyl group, R.sup.

Abstract: In a method of vacuum casting molten metal sucked from a molten metal reservoir into a cavity held under a reduced pressure by opening a gate having been blocking the communication between the molten metal reservoir and the cavity, the trapping of gas and foreign matter in the cavity is effectively prevented. To this end, an accommodation space for accommodating gas and foreign matter is provided in the molten metal reservoir. The accommodation space is provided at a position from which the accommodated matter is not sucked into the cavity.

Abstract: A sorter for sorting sheets out is provided with a bin unit including a plurality of bins having specified length and width and a bin shifting mechanism for shifting the bin unit upward and downward. The respect ire bins are vertically spaced apart and adapted for placing the sorted sheets thereon. The sorter is further provided with a first detector for detecting that the bin unit has been moved down to a home position region defined in a lower portion of the sorter, and a shift controller for controlling the bin shifting mechanism. The shift controller shifts the bin unit downward until the first detector conducts the detection when the bin unit is not in the home position region when the power is applied the sorter. Accordingly, the home position of the bin unit can be detected accurately with a simple structure.

Abstract: A variable resistor including a resistive element and a conductive element supported by a plate. Contacting terminals are provided on one or more ends of each element. A carriage is slidably supported above the elements and a conductive roller is supported from the carriage by a suspension member that biases the conductive roller against the elements. The effective length of the current path through the resistive element is varied by using the conductive roller to electrically connect the two elements to one another along different portions of their length. In a preferred embodiment, the carriage moves under the guidance of at least one guide bar and the conductive roller is suspended from the carriage by a coiled spring.

Abstract: A variable resistor includes strip-shaped conductive and resistive elements on an insulator plate. A cylindrical-shaped, conductive roller element can be rolled over the conductive and resistive elements to vary resistance. Thereby, substantially all sliding movement or contact is eliminated, which eliminates noise and prevents excessive wear.